Waverly Advisors 13F: Adds $1.6M to ABT Stake

Waverly Advisors Expands Abbott Laboratories Position

Waverly Advisors raised its stake in Abbott Laboratories NYSE:ABT during the period ended May 15, 2026, according to a Form 13F filing with the Securities and Exchange Commission. The filing reflects holdings as of that reporting date and may not show the firm's current position.

Details of the Portfolio Move

The firm picked up 17,977 shares, which worked out to a 16.3% increase from its prior count of 110,077 shares. That addition brought Waverly Advisors' total ownership up to 128,054 shares. Based on the cost basis provided in the paperwork, the overall value of the stake sits at approximately $11.64 million.

Abbott Laboratories Stock Performance

Abbott Laboratories shares have traded across a 52-week band spanning from a low of $81.97 up to a high of $132.03. The healthcare company carries a forward P/E ratio of 17.26 alongside a trailing price-to-earnings ratio of 33.77. Because 13F disclosures look backward at completed quarters, these filings offer a snapshot of past institutional trades rather than real-time adjustments.

Recent Earnings and Financial Health

Abbott Laboratories generated $46.58 billion in revenue over the trailing period, accompanied by a revenue growth rate of 13.0%. The company posted an earnings per share figure of $3.10, paired with a net margin of 11.6% and a return on equity of 10.58%. Investors will look ahead to the company's next earnings report scheduled for October 21, 2026, to gauge ongoing operational performance.

Dividend Profile

The healthcare firm rewards shareholders with an annual dividend yield of 2.41%. This payout is backed by a dividend payout ratio of 78.71%, indicating how much of its earnings the company returns to investors via dividends.

Wall Street Analyst Views

Wall Street firms remain mostly positive on the stock. On October 16, 2026, TD Cowen reiterated its Buy rating and a $135.00 price target. Earlier on October 7, 2026, Barclays initiated coverage with an Overweight rating and a $120.00 price target. Rothschild & Co upgraded the stock to Buy on October 2, 2026, raising its target from $119.00 to $127.00. Overall, the stock carries a Strong Buy consensus rating from 26 analysts with a mean price target of $120.72.

Inside Abbott Laboratories

Abbott Laboratories, headquartered in Abbott Park, Illinois, discovers, develops, manufactures, and sells health care products globally. The company operates through four main divisions focused on established pharmaceuticals, diagnostics, nutritional products, and medical devices. Founded in 1888, the firm employs roughly 122,000 workers worldwide.

What to Watch at Abbott Laboratories

Investors tracking Waverly Advisors will need to wait for subsequent SEC disclosures to see if the firm continues building its healthcare holdings. Market participants will also monitor upcoming earnings results in October and broader market conditions to see how the stock responds. These historical filings serve as a rearview mirror for institutional moves, so checking newer updates remains essential.